HALO Earnings & Financial Statements
Halozyme Therapeutics, Inc.
$110.42
+$0.58(+0.53%)
69
Overall
60
Value
83
Tech
65
Quality
Market Cap
$12.53B
Volume
1.85M
52W Range
$61.23 - $116.85
Target Price
$99.00
HALO earnings and financial statements: Halozyme Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
HALO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M |
| Cost of revenue | $228.77M | $159.42M | $192.36M | $139.30M | $81.41M |
| Operating income | $469.01M | $551.48M | $337.57M | $267.53M | $275.90M |
| EBITDA | $580.56M | $663.89M | $459.27M | $323.35M | $259.04M |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $907.48M |
| Shareholders’ equity | $48.81M | $363.82M | $83.81M | $169.80M | $196.95M |
| Cash and equivalents | $133.82M | $115.85M | $118.37M | $234.19M | $118.72M |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.25M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $651.56M | $479.06M | $388.57M | $240.11M | $299.44M |
| Capital expenditure | -$6.97M | -$10.70M | -$15.29M | -$4.81M | -$1.46M |
| Free cash flow | $644.59M | $468.37M | $373.28M | $235.30M | $297.98M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HALO | $110.42 | +0.5% | 1.85M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Halozyme Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW